Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Must have given written informed consent (signed and dated) and any authorizations required by local law~2. 18 to 75 years old (inclusive)~3. Male or female with a diagnosis of PBC, by at least two of the following criteria:~   * History of AP above ULN for at least six months~  * Positive Anti-Mitochondrial Antibodies (AMA) titers (\>1/40 on immunofluorescence or M2 positive by enzyme linked immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies~  * Documented liver biopsy result consistent with PBC~4. On a stable and recommended dose of UDCA for the past twelve months~5. AP ≥ 1.67 × ULN~6. For females of reproductive potential, use of at least one barrier contraceptive and a second effective birth control method during the study and for at least two weeks after the last dose. For male subjects, use of appropriate contraception (e.g., condoms), so their female partners of reproductive potential do not become pregnant during the study and for at least two weeks after the last dose~Exclusion Criteria:~1. A medical condition, other than PBC, that in the investigator's opinion would preclude full participation in the study or confound its results (e.g., cancer on active treatment)~2. AST or ALT \> 3 × ULN~3. Total bilirubin \> 2 × ULN~4. Auto-immune hepatitis~5. Primary sclerosing cholangitis~6. Known history of alpha-1-Antitrypsin deficiency~7. Known history of chronic viral hepatitis~8. Creatine kinase above ULN~9. Serum creatinine above ULN~10. For females, pregnancy or breast-feeding~11. Use of colchicine, methotrexate, azathioprine, or systemic steroids in the two months preceding screening~12. Current use of fibrates, including fenofibrates, or simvastatin~13. Use of an experimental treatment for PBC~14. Use of experimental or unapproved immunosuppressant~15. Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Dose (Type: PLACEBO_COMPARATOR): Placebo Capsule Two Capsules Daily
- Seladelpar / MBX-8025 50 mg Dose (Type: EXPERIMENTAL): MBX-8025 50 mg capsule One Capsule Daily
- Seladelpar / MBX-8025 200 mg Dose (Type: EXPERIMENTAL): MBX-8025 100 mg capsules (2 taken once daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).